Cargando…

Build a Sustainable Vaccines Industry with Synthetic Biology

The vaccines industry has not changed appreciably in decades regarding technology, and has struggled to remain viable, with large companies withdrawing from production. Meanwhile, there has been no let-up in outbreaks of viral disease, at a time when the biopharmaceuticals industry is discussing dow...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitney, Richard I., Bell, Jennifer, Philp, Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834237/
https://www.ncbi.nlm.nih.gov/pubmed/33431228
http://dx.doi.org/10.1016/j.tibtech.2020.12.006
_version_ 1783642238658543616
author Kitney, Richard I.
Bell, Jennifer
Philp, Jim
author_facet Kitney, Richard I.
Bell, Jennifer
Philp, Jim
author_sort Kitney, Richard I.
collection PubMed
description The vaccines industry has not changed appreciably in decades regarding technology, and has struggled to remain viable, with large companies withdrawing from production. Meanwhile, there has been no let-up in outbreaks of viral disease, at a time when the biopharmaceuticals industry is discussing downsizing. The distributed manufacturing model aligns well with this, and the advent of synthetic biology promises much in terms of vaccine design. Biofoundries separate design from manufacturing, a hallmark of modern engineering. Once designed in a biofoundry, digital code can be transferred to a small-scale manufacturing facility close to the point of care, rather than physically transferring cold-chain-dependent vaccine. Thus, biofoundries and distributed manufacturing have the potential to open up a new era of biomanufacturing, one based on digital biology and information systems. This seems a better model for tackling future outbreaks and pandemics.
format Online
Article
Text
id pubmed-7834237
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78342372021-01-26 Build a Sustainable Vaccines Industry with Synthetic Biology Kitney, Richard I. Bell, Jennifer Philp, Jim Trends Biotechnol Opinion The vaccines industry has not changed appreciably in decades regarding technology, and has struggled to remain viable, with large companies withdrawing from production. Meanwhile, there has been no let-up in outbreaks of viral disease, at a time when the biopharmaceuticals industry is discussing downsizing. The distributed manufacturing model aligns well with this, and the advent of synthetic biology promises much in terms of vaccine design. Biofoundries separate design from manufacturing, a hallmark of modern engineering. Once designed in a biofoundry, digital code can be transferred to a small-scale manufacturing facility close to the point of care, rather than physically transferring cold-chain-dependent vaccine. Thus, biofoundries and distributed manufacturing have the potential to open up a new era of biomanufacturing, one based on digital biology and information systems. This seems a better model for tackling future outbreaks and pandemics. Elsevier Ltd. 2021-09 2021-01-08 /pmc/articles/PMC7834237/ /pubmed/33431228 http://dx.doi.org/10.1016/j.tibtech.2020.12.006 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Opinion
Kitney, Richard I.
Bell, Jennifer
Philp, Jim
Build a Sustainable Vaccines Industry with Synthetic Biology
title Build a Sustainable Vaccines Industry with Synthetic Biology
title_full Build a Sustainable Vaccines Industry with Synthetic Biology
title_fullStr Build a Sustainable Vaccines Industry with Synthetic Biology
title_full_unstemmed Build a Sustainable Vaccines Industry with Synthetic Biology
title_short Build a Sustainable Vaccines Industry with Synthetic Biology
title_sort build a sustainable vaccines industry with synthetic biology
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834237/
https://www.ncbi.nlm.nih.gov/pubmed/33431228
http://dx.doi.org/10.1016/j.tibtech.2020.12.006
work_keys_str_mv AT kitneyrichardi buildasustainablevaccinesindustrywithsyntheticbiology
AT belljennifer buildasustainablevaccinesindustrywithsyntheticbiology
AT philpjim buildasustainablevaccinesindustrywithsyntheticbiology